Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 7.43% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (up 7.43% YoY) and the FY2025 annual result came in at $1.8 million, up 10.76% from the prior year.
• Non-Current Deferred Tax Liability rose to $1.8 million in Q4 2025 per AAPG's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for AAPG reached as high as $2.5 million in Q4 2022 and fell as low as $1.7 million in Q4 2024.
• A 4-year average of $2.0 million and a median of $2.0 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability retreated 24.14% — and 2025, when it climbed 7.43%.
• Year by year, Non-Current Deferred Tax Liability stood at $2.5 million in 2022, then slipped by 9.79% to $2.2 million in 2023, then fell by 24.14% to $1.7 million in 2024, then advanced by 7.43% to $1.8 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.8 million, $1.7 million, and $2.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.